PDF factsheet
      Z

immune checkpoint inhibition in multiple myeloma for all type of patients, clinical trials results

pembrolizumab + pomadoline + dexamethasone versus pomadoline + dexamethasone
KEYNOTE-183, 2018
NCT02576977
pembrolizumab, Pomalidomide and low-dose Dexamethasone
versus
Pomalidomide and low-dose Dexamethasone
refractory or relapsed and refractory Multiple Myeloma (rrMM)open-design
Follow-up duration: 7.8 mo / 8.6 mo (median)
pembrolizumab, lenalidomide, dexametahsone versus lenalidomide, dexamethasone
KEYNOTE-185, 2018
NCT02579863

versus
lenalidomide and low-dose dexamethasone
newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant open-design

  Options


in first

in second

  Filter